Publicatie

Publication date

Rotavirus infection.

Verberk, J.D.M., Suijkerbuijk, A.W.M., Vennema, H., Hooiveld, M., Melker, H.E. de, Bruijning-Verhagen, P. Rotavirus infection. In: Alebeek, R. van, Benschop, K., Benthem, B. van, Brinnendijk, R. van, Bogaards, J.A., Bootsma, H.J., Brinkman, I., Bruijning-Verhagen, P., Buisman, A., Cremer, J., Donken, R., Duizer, E., Els, C.A.C.M. van, Ende, A. van der, Friesema, I.H.M., Gent, M. van, Gier, B. de, Gouma, S., Heiningen, F. van, Hoek, W. van der, Hofstraat, S., Hooiveld, M., Hulshof, K., Janga-Jansen, A., Jochemsen, P., Kaaijk, P., Kassteele, J. van de, Kasteren, P.B van, Kemmeren, J.M., Kerkhof, H. van den, King, A.J., Klis, F.R.M. van der, Knol, M.J., Korthals-Altes, H., Lehmann, B., Lier, E.A. van, Luinstra-Passchier, M., Luytjes, W., Maas, N.A.T. van der, Mangen, M.J.J., McDonald, S.A., Meijer, A., Melker, H.E. de, Mollema, L., Monge, S., Nielen, M., Nottermans, D.W., Pasmans, H., Pinelli, E., Prettner, R., Qendri, V., Reubsaet, F.A.G., Romijnders, K., Rots, N.Y., Ruijs, W.L.M., Schurink-van 't Klooster, T.M., Slobbe, J. van, Suijkerbuijk, A.W.M., Teirlinck, A.C., Veldhuizen, I.K., Vennema, H., Verberk, J.D.M., Vos, R.A., Weele, P. van der, Woestenberg, P.J., Woudenberg, T. The National Immunisation Programme in the Netherlands : surveillance and developments in 2016-2017. Bilthoven: RIVM, 2017. 180-186
• In 2016, a second low-endemic rotavirus season was observed, similar to the one in 2014, while 2015 and 2017 showed average rotavirus epidemics, comparable to the years prior to 2014. Together, these observations suggest a possible transition from an annual to a biennial rotavirus epidemic pattern in the Netherlands.
• G9P[8] was the most prevalent genotype in 2016.
• The Dutch Health Council has recommended to the Ministry of Health, Welfare and Sport to vaccinate high-risk group children (premature children, children with low birth weight or congenital pathology). In addition, they state that the Health Council is positive towards mass vaccination incorporated in the NIP, however, they mention that this will not be cost-effective seen the current vaccine prices. The RIVM has published a background document providing up-to-date information to facilitate the Health Council in preparing their recommendation. (aut. ref.)